Medicare Advantage Plans More Likely to Use Prior Authorization for Cancer Treatments, Study Finds
Medicare Advantage (MA) plans are significantly more likely to require prior authorization for clinician-administered or infused cancer treatments compared to traditional Medicare, according to a 2023 analysis by the Kaiser Family Foundation (KFF). This disparity raises concerns about potential delays in care for patients enrolled in MA, which covers about 40% of Medicare beneficiaries.
Under traditional Medicare, patients can generally receive covered treatments without pre-approval, though providers may still face scrutiny. In contrast, MA plans—offered by private insurers—often impose additional steps to approve high-cost therapies, including chemotherapy and immunotherapy. “This creates a barrier for patients who may not have the time or resources to navigate these processes,” said Dr. Sarah Jane Collins, a health policy researcher at KFF.
How Prior Authorization Affects Patient Access
Prior authorization requires healthcare providers to submit documentation to insurers demonstrating that a treatment is medically necessary. While intended to curb unnecessary care, critics argue it can delay treatment. The KFF study found that 68% of MA plans required prior authorization for at least one infused cancer therapy in 2022, compared to 22% of traditional Medicare parts C and D.
“Providers report that the process can take days or weeks, which is unacceptable for patients with aggressive cancers,” said Dr. Michael Torres, a medical oncologist at the American Society of Clinical Oncology (ASCO). “Some patients end up paying out-of-pocket or forgoing treatment altogether.”
Policy Implications and Patient Advocacy
The disparity has sparked calls for reform. In 2023, the Centers for Medicare & Medicaid Services (CMS) proposed rules to limit prior authorization requirements for certain cancer treatments, but implementation remains pending. Patient advocacy groups argue that MA plans should align more closely with traditional Medicare’s standards.
“Patients shouldn’t face different rules based on their insurance type,” said Linda Reynolds, executive director of the National Patient Advocate Foundation. “This is about equity in care.”
What This Means for Beneficiaries
For Medicare beneficiaries, the difference matters. Those in MA plans may need to work closely with their providers to understand coverage details. “It’s crucial to review your plan’s formulary and prior authorization policies annually,” advised Emily Zhang, a Medicare counselor at AARP.
Patients facing delays should contact their plan’s customer service or seek assistance from a Medicare advisor. “You have the right to appeal decisions,” Zhang added.
Key Takeaways
- Medicare Advantage plans are more likely to require prior authorization for cancer treatments than traditional Medicare.
- 68% of MA plans required prior authorization for infused therapies in 2022, compared to 22% of traditional Medicare parts C and D.
- Critics argue the process can delay care, particularly for patients with time-sensitive conditions.
- CMS is considering reforms, but beneficiaries should proactively review their plans and seek assistance when needed.